Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part II: Assessment of Safety

Aim. We aimed to assess safety and effectiveness of class III antiarrhythmic drug Refralon for conversion of atrial fibrillation (AFib) and flutter (AFl) in post-registration trial and to compare data of primary center (National medical research center in cardiology) with data of other hospitals.

Material and Methods. We performed retrospective cohort study in 727 patients (451 enrolled in primary center and 276 enrolled in other hospitals) admitted between June 24, 2014 and June 24, 2019. Refralon was administered for conversion of AFib and AFl in intense care units in escalating doses (10-30 micrograms/kg) intravenously.

Results. Conversion of AFib and AFl into sinus rhythm was achieved in 53,6% after administration of 10 mcg/kg dose, in 73% after administration of 20 mcg/kg dose and in 91,6% after administration of Refralon in dose up to 30 mcg/kg. No mortality and no major adverse cardiac events registered in our study. Asystole >3.0 sec observed in 5% (35 of 727) of patients): in 5% (24 of 451) of patients enrolled in primary center and in 4% (11 of 276) of patients enrolled in other hospitals; 95% confidence interval (CI) [-0.09; 0.113]. Asystole> 5.0 s observed in 1.7% of patients who further required non-urgent implantation of a permanent pacemaker due to manifestations of sinus node dysfunction. Cardiac conduction disturbances (exclusively sinus bradycardia) were registered in 7% (53 of 727) patients: in 8% (37 of 451) of patients enrolled in primary center and in 6% (17 of 276) of patients enrolled in other hospitals; 95% CI: [-0.1; 0.15]. Only 0.14% of patients had symptomatic sinus bradycardia that resolved after atropine injection. Ventricular arrhythmias (exclusively Torsade de pointes tachycardia in excessive QT interval prolongation) were registered in 1.7% (12 of 727) patients: in 2% (9 of 451) of patients in primary center and in 1% (3 of 276) of patients of other hospitals; 95% CI: [-0.06; 0.08]. QTc interval prolongation to values >500 ms documented in 19% (138 of 727) of patients: in 21% (95 of 451) of patients in primary center and in 16% (43 of 276) of patients in other hospitals; 95% CI: [-0.13; 0.24].

Conclusion: In post-registration multicenter trial Refralon demonstrated good safety profile in conversion of AFib and AFl. Potential risk of TdP tachycardia mandates precautions with the use of the drug. In other hospitals Refralon did not demonstrate lower safety than in primary medical center.

1. Bulanova NA, Stazhadze LL, Alekseeva LA, et al. Prevalence of atrial fibrillations among patients under observation by an outpatient clinic. Kardiologiia. 2011;51(12):29-35 (In Russ.)

2. Shkolnikova MA, Zhdanov DA, Ildarova RA, et al. Atrial fibrillation among russian men and women aged 55 years and older: prevalence, mortality, and associations with biomarkers in a populationbased study. J Geriatr Cardiol. 2020;17(2):74-84. DOI:10.11909/j.issn.1671-5411.2020.02.002.

3. Boytsov SA, Demkina AE, Oshchepkova EV, et al. Progress and problems of practical cardiology in Russia at the present stage. Kardiologiia. 2019; 59(3): 53-59. (In Russ.) [DOI:10.18087/cardio.2019.3.10242.

4. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609-78. DOI:10.1093/europace/euw295.

5. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2014;64(21):247-78. DOI:10.1161/CIR.0000000000000040.

6. Golitsyn SP, Panchenko EP, Kropacheva ES, et al. Eurasian clinical recommendations on diagnosis and treatment of atrial fibrillation. Eurasian Journal of Cardiology. 2019;(4):4-85 (In Russ.)

7. Camm AJ. Hopes and disappointments with antiarrhythmic drugs. Int J Cardiol. 2017;237:71-4 DOI:10.1016/j.ijcard.2017.03.056.

8. Yuricheva YuA, Sokolov SF, Golitsyn SP, et al. A novel III class antiarryhthmic, niferidil, as an effective medication for the sinus rhythm recovery in patients with persistent atrial fibrillation. J Arrhythmol. 2012;70(70):32-43 (In Russ.)

9. Maykov EB, Yuricheva YuA, Mironov NYu, et al. Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter. Ter Arkhiv. 2015;87(1):38-48 (In Russ.) DOI: 10.17116/terarkh201587138-48.

10. Mironov NYu, Vlodzyanovskiy VV, Yuricheva YuA et al. Safety and effectiveness of electrical and pharmacological cardioversion in persistent atrial fibrillation. Part I: study rationale, design and assessment of effectiveness. Rational Pharmacotherapy in Cardiology. 2018;14(5):664-9 (In Russ.) DOI:10.20996/1819-6446-2018-14-5-664-669.

11. Mironov NYu, Vlodzyanovskiy VV, Yuricheva YuA, et al. Safety and effectiveness of electrical and pharmacological cardioversion in persistent atrial fibrillation. Part 2: assessment of safety. Rational Pharmacotherapy in Cardiology. 2018;14(6):826-30 (In Russ.) DOI:10.20996/1819-6446-2018-14-6-826-830.

12. Mironov NYu, Yuricheva YuA, Vlodzyanovskiy VV, et al. Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part I: Study Rationale, Design and Assessment of Effectiveness. Rational Pharmacotherapy in Cardiology. 2021;17(2):193-9 (In Russ.) DOI:10.20996/1819-6446-2021-03-05.

13. Freemantle N, Lafuente-Lafuente C, Mitchell S et al. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace. 2011;13(3):329-45. DOI:10.1093/europace/euq450.

14. Trinkley KE, Page RL 2nd, Lien H, et al. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin. 2013;29(12):1719-26. DOI:10.1185/03007995.2013.840568.

15. Akramova E.G. Dispersion of QT interval during Holter in patients with chronic obstructive pulmonary disease and bronchial asthma. Clinical Medicine. 2012;90(1):25-8 (In Russ.)

16. Akramova E.G. Сlinical role of cardiac examination in COPD patients. Russian Journal of Cardiology. 2012;17(1):41-7 (In Russ.) DOI:10.15829/1560-4071-2012-1-41-47.

17. Kirchhof CJ, Allessie MA. Sinus node automaticity during atrial fibrillation in isolated rabbit hearts. Circulation. 1992;86(1):263-71. DOI:10.1161/01.CIR.86.1.263.

18. Abramochkin DV, Kuzmin VS, Rosenshtraukh LV. A new class III antiarrhythmic drug niferidil prolongs action potentials in guinea pig atrial myocardium via inhibition of rapid delayed rectifier. Cardiovascular Drugs and Therapy. 2017;31(5-6):525-33. DOI:10.1007/s10557-017-6762-x.

19. Mironov NYu, Golitsyn SP, Sokolov SF, et al. Electrophysiological Effects and Antiarrhythmic Activity of Novel Domestic Class III Antiarrhythmic Drug Niferidil in Patients with Paroxismal Supraventricular Tachycardia. Experimental and Clinical Pharmacology. 2012;75(10):16-21 (In Russ.)

20. Mironova ES, Mironova NA, Sharf TV, et al. Autoantibodies to M2-cholinoreceptors as a potential development factor of arrhythmia in patients with paroxysmal atrial fibrillation. Ter Arkhiv. 2019;91(9):101-7 (In Russ.) DOI:10.26442/00403660.2019.09.000280].

21. Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation. 2012;125(2):381-9. DOI:10.1161/CIRCULATIONAHA.111.019927.

22. Mironova ES, Mironov NY, Mironova NA, et al. Electrophysiological Cardiac Parameters and Results of Antiarrhythmic Treatment in Patients with Paroxysmal Atrial Fibrillation (Lone and Associated with Arterial Hypertension). Kardiologiia. 2019;59(8):39-46 (In RussDOI:10.18087/cardio.2019.8.n644.

23. Waldo AL, Feld GK. Inter-relationships of atrial fibrillation and atrial flutter mechanisms and clinical implications. J Am Coll Cardiol. 2008;51(8):779-86. DOI:10.1016/j.jacc.2007.08.066.